Brokerages Set AnaptysBio Inc (ANAB) PT at $132.70

AnaptysBio Inc (NASDAQ:ANAB) has received a consensus recommendation of “Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $132.70.

ANAB has been the topic of a number of research analyst reports. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research cut AnaptysBio from a “hold” rating to a “sell” rating in a report on Friday, November 9th. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Friday, November 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $121.00 target price on shares of AnaptysBio in a report on Tuesday, August 7th. Finally, JPMorgan Chase & Co. began coverage on AnaptysBio in a report on Wednesday. They issued an “overweight” rating and a $115.00 target price on the stock.

AnaptysBio stock traded up $0.94 during midday trading on Thursday, reaching $73.95. The stock had a trading volume of 184,747 shares, compared to its average volume of 374,042. AnaptysBio has a twelve month low of $62.56 and a twelve month high of $134.00. The stock has a market capitalization of $1.98 billion, a P/E ratio of -48.65 and a beta of 3.47.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.05. The firm had revenue of $5.00 million during the quarter. As a group, analysts predict that AnaptysBio will post -2.79 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in shares of AnaptysBio by 11.7% during the third quarter. FMR LLC now owns 3,935,467 shares of the biotechnology company’s stock worth $392,642,000 after purchasing an additional 410,918 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of AnaptysBio by 11.1% during the third quarter. Janus Henderson Group PLC now owns 3,143,155 shares of the biotechnology company’s stock worth $313,592,000 after purchasing an additional 312,833 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of AnaptysBio by 20.0% during the third quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after purchasing an additional 308,517 shares in the last quarter. BlackRock Inc. lifted its stake in shares of AnaptysBio by 11.1% during the third quarter. BlackRock Inc. now owns 1,627,140 shares of the biotechnology company’s stock worth $162,341,000 after purchasing an additional 162,516 shares in the last quarter. Finally, OppenheimerFunds Inc. lifted its stake in shares of AnaptysBio by 5.2% during the second quarter. OppenheimerFunds Inc. now owns 1,101,887 shares of the biotechnology company’s stock worth $78,278,000 after purchasing an additional 54,773 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Featured Article: How does inflation affect different investments?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply